General Archives - Gilde Healthcare

Neuigkeiten
& Einblicke

Gilde Healthcare company ProVerum Announces Completion of Enrollment for the ProVIDE Clinical Study for BPH and First-use of its New Flexible, Steerable Delivery System

ProVerum Limited, an Irish medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor's office, today announced completion of enrollment of the ProVIDE pivotal clinical trial to evaluate the safety and effectiveness of the ProVee System, a 'stent-like' expander designed to  gently 'open-up' the obstructed urethra and alleviate the symptoms caused by BPH....
21. März 2024

Gilde Healthcare veräussert RAD-x an ein konsortium aus Swiss Life Asset Managers und Vesper Infrastructure Fund I

test Gilde Healthcare´s Private Equity Fund (“Gilde Healthcare”), ein auf das Gesundheitswesen spezialisierter Investor, hat eine bindende Vereinbarung über den Verkauf seiner Mehrheitsbeteiligung an RAD-x an ein Konsortium aus Swiss Life Asset Managers und Vesper Next Generation Infrastructure Fund I unterzeichnet. Gilde Healthcare investierte in RAD-x und gründete das Unternehmen gemeinsam mit dem Management im Jahr […]

Gilde Healthcare company NIZO acquires lactic acid facility and strengthens partnership with DSM-firmenich

test NIZO food research B.V. (“NIZO”) is proud to announce the signature of a long-term contract manufacturing partnership with dsm-firmenich. This strategic alliance encompasses the acquisition of the neighboring lactic acid facility from Vika Nutrition B.V., a Givaudan group company. With this move, NIZO widens its capabilities and secures the opportunity to develop the NIZO Food […]

Gilde Healthcare co-leads oversubscribed €54 Million Series B round of Argá Medtech

Argá Medtech, a company developing a next-generation cardiac ablation system for treating cardiac arrhythmias, including atrial fibrillation (AF), announced it closed a €54M oversubscribed Series B raise co-led by Gilde Healthcare with existing investors, Advent Life Sciences (U.K.) and Earlybird Venture Capital (Germany), as well as an...

Gilde Healthcare leads $125 Million Equity Financing of Mainstay Medical

Funding to accelerate commercial growth and expand clinical and health economic evidence for ReActiv8® Restorative NeuromodulationTM System Mainstay Medical Holdings plc today announced an equity financing in which it will receive gross proceeds of US$125 million. Mainstay intends to use the funds to support the company’s continued...

Gilde Healthcare portfolio company Scharenborg Group appoints Johannes Schneider Littfeld as Chairman

The Scharenborg Group, a leading footcare technology firm has appointed Johannes Schneider Littfeld as Chairman to the Advisory Board. Johannes is an experienced executive in the MedTech- and patient care industry. He spent 15 years in senior management of Otto Bock, the global leader in Orthopedic Technology....

Amphista Therapeutics announces in vivo efficacy and CNS activity of its protein degraders

First demonstration of efficacy in disease-relevant in vivo models for an orally delivered bifunctional non-cereblon / non-VHL-based protein degrader Deep degradation of target protein is achieved in a rapid, sustained, and highly selective manner Successful achievement of efficient CNS delivery for multiple degraders and demonstration of significant...

James Leech Joins Moximed as Chief Financial and Strategy Officer

Leech brings expertise in financing and scaling growth-stage medtech companies. Moximed, a medical device company on a mission to improve the standard of care for people with knee osteoarthritis (OA), today announced that James Leech has joined the company as Chief Financial and Strategy Officer. “James adds...

Gilde Healthcare company AM-Pharma initiates Phase 2 trial of Ilofotase alfa for cardiac surgery-associated renal damage

Trial will evaluate ilofotase alfa as a treatment to prevent renal damage in at-risk patients following open heart surgery Ilofotase alfa’s clinical record of renal protective effects supports therapeutic potential in underserved and high-need indication AM-Pharma B.V. today announced that the first patients have been treated in...
Loading...
These were all messages
54f5ec0dc6